Schadendorf, D., Luke, J. J., Ascierto, P. A., Long, G. V., Rutkowski, P., Khattak, A., . . . Scolyer, R. A. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Citação norma ChicagoSchadendorf, Dirk, Jason John Luke, Paolo A. Ascierto, Georgina V. Long, Piotr Rutkowski, Adnan Khattak, Luis de la Cruz Merino, y Richard A. Scolyer. Pembrolizumab Versus Placebo As Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Outcomes in Histopathologic Subgroups From the Randomized, Double-blind, Phase 3 KEYNOTE-716 Trial. 2024.
Citação norma MLASchadendorf, Dirk, et al. Pembrolizumab Versus Placebo As Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Outcomes in Histopathologic Subgroups From the Randomized, Double-blind, Phase 3 KEYNOTE-716 Trial. 2024.